These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20071289)

  • 21. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate.
    Schaeffer AJ; Montorsi F; Scattoni V; Perroncel R; Song J; Haverstock DC; Pertel PE
    BJU Int; 2007 Jul; 100(1):51-7. PubMed ID: 17552953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.
    Henry DC; Bettis RB; Riffer E; Haverstock DC; Kowalsky SF; Manning K; Hamed KA; Church DA
    Clin Ther; 2002 Dec; 24(12):2088-104. PubMed ID: 12581547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.
    Mombelli G; Pezzoli R; Pinoja-Lutz G; Monotti R; Marone C; Franciolli M
    Arch Intern Med; 1999 Jan; 159(1):53-8. PubMed ID: 9892331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial.
    Pimentel FL; Dolgner A; Guimarães J; Quintas M; Mário-Reis J
    J Chemother; 1998 Apr; 10(2):122-7. PubMed ID: 9603637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
    Nicodemo AC; Robledo JA; Jasovich A; Neto W
    Int J Clin Pract; 1998 Mar; 52(2):69-74. PubMed ID: 9624783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected].
    Iravani A; Tice AD; McCarty J; Sikes DH; Nolen T; Gallis HA; Whalen EP; Tosiello RL; Heyd A; Kowalsky SF
    Arch Intern Med; 1995 Mar; 155(5):485-94. PubMed ID: 7864704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.
    Bach D; van den Berg-Segers A; Hübner A; van Breukelen G; Cesana M; Plétan Y
    J Urol; 1995 Jul; 154(1):19-24. PubMed ID: 7776420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
    Cox CE; Marbury TC; Pittman WG; Brown GL; Auerbach SM; Fox BC; Yang JY
    Clin Ther; 2002 Feb; 24(2):223-36. PubMed ID: 11911553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single topical agent is clinically equivalent to the combination of topical and oral antibiotic treatment for otitis externa.
    Roland PS; Belcher BP; Bettis R; Makabale RL; Conroy PJ; Wall GM; Dupre S; Potts S; Hogg G; Weber K;
    Am J Otolaryngol; 2008; 29(4):255-61. PubMed ID: 18598837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
    Esposito S; Noviello S; Leone S; Marvaso A; Drago L; Marchetti F;
    J Chemother; 2006 Oct; 18(5):494-501. PubMed ID: 17127226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study.
    Klimberg I; Shockey G; Ellison H; Fuller-Jonap F; Colgan R; Song J; Keating K; Cyrus P
    Curr Med Res Opin; 2005 Aug; 21(8):1241-50. PubMed ID: 16083534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group.
    Krcmery S; Naber KG
    Int J Antimicrob Agents; 1999 Feb; 11(2):133-8. PubMed ID: 10221416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
    Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
    J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
    Wolfhagen MJ; Hoepelman AI; Verhoef J
    Antimicrob Agents Chemother; 1990 Mar; 34(3):409-12. PubMed ID: 2110437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin].
    Arakawa S; Takagi S; Matsumoto O; Kamidono S; Sengoku A; Hazama M; Yamazaki H; Hamami G; Okamoto Y; Tanaka H
    Jpn J Antibiot; 1991 Jul; 44(7):718-31. PubMed ID: 1909383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.
    Auquer F; Cordón F; Gorina E; Caballero JC; Adalid C; Batlle J;
    Clin Microbiol Infect; 2002 Jan; 8(1):50-4. PubMed ID: 11906502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections.
    Iravani A
    Am J Med; 1993 Mar; 94(3A):89S-96S. PubMed ID: 8452189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.
    Meagher AK; Forrest A; Dalhoff A; Stass H; Schentag JJ
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2061-8. PubMed ID: 15155200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciprofloxacin: an update on clinical experience.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Becker N; August R
    Am J Med; 1987 Apr; 82(4A):381-6. PubMed ID: 3555063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.